Diabetes Giants Battle Outside of Their Usual Arena
Novo Nordisk makes headway in diabetes and bleeding disorders as Sanofi and Merck continue to grapple over cholesterol.
3 Stocks to Rule the Next Decade of Diabetes Treatments
Merck, Sanofi, and Novo Nordisk hold court among suitors to diabetes' growing global market.
Could This New Drug Application Lead to a Giant Leap for MannKind?
MannKind recently resubmitted its NDA to the Food and Drug Administration for the approval of its eagerly anticipated inhalable insulin, Afrezza. Will this new effort lead to an approval or a third rejection for the polarizing company?